Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Double-blind Placebo-controlled Comparative Randomized Study of the Tolerability, Safety, Immunogenicity and Prophylactic Efficacy of the EpiVacCorona Peptide Antigen-based Vaccine for the Prevention of COVID-19, With the Participation of 3000 Volunteers Aged 18 Years and Above (Phase III-IV)

NCT04780035 is registered in ClinicalTrials.gov with Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" as lead sponsor.

NCT NCT04780035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04780035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Double-blind Placebo-controlled Comparative Randomized Study of the Tolerability, Safety, Immunogenicity and Prophylactic Efficacy of the EpiVacCorona Peptide Antigen-based Vaccine for the Prevention of COVID-19, With the Participation of 3000 Volunteers Aged 18 Years and Above (Phase III-IV)
Lead sponsor
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"
Phase
Phase 3
Overall status
Completed
Start date
November 27, 2020
Completion date
December 20, 2021
Enrollment
3,000 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19